PRJNA664320
Oral microbiome in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy
Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 90 patients with relapsed/refractory multiple myeloma (MM) treated with Ixazomib-Thalidomide-Dexamethasone. Sequencing was performed at the Joint Microbiome Facility of the Medical University of Vienna and the University of Vienna under the project ID JMF-2001-4.